ME3183 is an oral unselective PDE4 inhibitor developed by Meiji Pharma USA Inc. to treat psoriasis, with potential for use in additional inflammatory conditions like AD in the near future [131,132]. The gene discussed is PDE4A; the disease is psoriasis.